RCKT Key Statistics, Chart & Performance
The current stock price of RCKT is 3.64 USD. In the past month the price increased by 11.32%. In the past year, price decreased by -64.69%.
RCKT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RCKT. When comparing the yearly performance of all stocks, RCKT is a bad performer in the overall market: 90.71% of all stocks are doing better.
RCKT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCKT. RCKT may be in some trouble as it scores bad on both profitability and health.
RCKT Financial Highlights
Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS increased by 19.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.46% | ||
| ROE | -76.8% | ||
| Debt/Equity | 0.06 |
RCKT Forecast & Estimates
21 analysts have analysed RCKT and the average price target is 7.86 USD. This implies a price increase of 116% is expected in the next year compared to the current price of 3.64.
For the next year, analysts expect an EPS growth of 22.11% and a revenue growth -100% for RCKT
RCKT Ownership
RCKT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About RCKT
Company Profile
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Company Info
ROCKET PHARMACEUTICALS INC
9 Cedarbrook Drive
Cranbury NEW JERSEY 08512 US
CEO: Gaurav Shah
Employees: 299
Phone: 16464409100
ROCKET PHARMACEUTICALS INC / RCKT FAQ
What does RCKT do?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Can you provide the latest stock price for ROCKET PHARMACEUTICALS INC?
The current stock price of RCKT is 3.64 USD. The price decreased by -1.89% in the last trading session.
Does ROCKET PHARMACEUTICALS INC pay dividends?
RCKT does not pay a dividend.
What is the ChartMill rating of ROCKET PHARMACEUTICALS INC stock?
RCKT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ROCKET PHARMACEUTICALS INC?
ROCKET PHARMACEUTICALS INC (RCKT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for RCKT stock?
ROCKET PHARMACEUTICALS INC (RCKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
Would investing in ROCKET PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RCKT.